Good afternoon, ladies and gentlemen, and welcome to the Quarter One 2021 Evolus Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to introduce your host for today's conference, Ms. Carol Ruth of The Ruth Group. Ma'am, please go ahead.

Thank you operator, and Welcome to everyone participating on today's call. This call is also being broadcast live over the Internet at evolus.com and a replay of the call will be available on the Company's website for 30 days. With me on the call today are David Moatazedi, President and Chief Executive Officer; Lauren Silvernail, Chief Financial Officer and Executive Vice President, Corporate Development and Rui Avelar, Chief Medical Officer and Head of R&D. In our remarks today, we will include statements that are considered forward-looking statements within the meaning of the United States securities laws. In addition, management may make additional forward-looking statements in response to your questions. Forward looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the Company's business, strategy, operations or financial performance. A detailed discussion of the risks and uncertainties that the Company faces is contained in its Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Actual results may differ materially from those expressed in or implied by the forward-looking statements. The Company undertakes no obligation to update, or review any estimate projection or forward-looking statements. Additionally, the discussion today will include non-GAAP financial measures. These non-GAAP measures should be considered in addition to and not as a substitute for or in isolation from our GAAP results. The reconciliation of GAAP to non-GAAP results may be found in our earnings release, which was furnished with our Form 8-K filed today with the SEC, and they also be found on our Investor Relations website at investors.evolus.com. Now, let me hand the call over to David, David?

Good afternoon and thank you, Carol. The first quarter of 2021 was a defining quarter for Evolus, we made significant strides in bringing clarity around our future for our shareholders, customers and employees. The quarter was defined by three major events that set the stage for the continued success of Jeuveau in the United States. The first of that was the resolution of both the ITC case and all outstanding future litigation. Second, we recapitalize the Company by eliminating senior and convertible debt and future milestones. We also completed an equity offering and received a settlement payment from our partner. These activities transformed our balance sheet, resulting in a pro forma cash position of $140 million on March 31st. Third, thanks to the strong showing support from our customers, our business has quickly bounced back since settlement in mid-February. To provide additional color on our business in the first quarter of 2021, we generated $12.2 million of net revenues, with most of the sales occurring after settlement in mid-February. We grew purchasing account 5,800 from 5,600 at year-end. And our cumulative reorder rate grew to 73%. We are pleased to see the trends in the first quarter persist into the second where we see increasing reorder rate and on average these accounts are repurchasing at higher volume. Overall, we are pleased to have all outstanding litigation -- legal issues resolved and the Company well capitalized for the future. The second quarter marks the first quarter since launch, in which we are free from all legacy challenges and for the first time, our customers can now partner with us for the long term and realize the full potential of our unique value proposition. We have proven that in esthetic company positioned against the younger demographic with a focus on technology creates a unique differentiation. The combination of these elements, has resulted in increasing trend across our business. In Q2 we believe Jeuveau achieved its highest sales quarter ever and reach annualized net revenue run rate of $100 million. Lastly, this month we are celebrating the two year anniversary since the launch of Jeuveau. The success we are seeing was about is directly related to the quality of this product and the extensive data generated over several years. And now I would like to turn it over to Rui Avelar to give you a quick update. Rui?

Thank you, David and good afternoon. Jeuveau has been on the market now for two years and we believe that over a million treatments will be completed. We have the benefit of having conducted three large Phase 3 clinical studies, including a head-to-head study against the market leader to support the approval of the product. Today, we announced the publication of two Phase 2 repeat dose open label one year studies that were part of the transparency global clinical program. The data from these studies were used to support the safety and efficacy of your vote. We wanted to share some interesting observations that we think will be helpful for our injectors and patients as well as investors. When treating patients with a biological drug the regulatory bodies such as the FDA want to see what happens to duration of effect with each repeat treatment since shortening of this interval can't be signal of building resistance against the drug or antibody formation. In both studies, the time interval between treatment did not shorten instead within treatment cohorts, the time interval actually trended longer after each successful treatment. Another interesting observation was the rate of adverse events after repeated treatments. It was noted that the rates of all adverse events and drug-related adverse events, both decreased with each successive treatment. We believe that these safety observations will continue to build injector and patient confidence in our product. Now let me turn it over to Lauren for a financial update.

Thank you, Ruien. Good afternoon, everyone. Earlier this year, we embarked on a strategy to recapitalize the Company. We started the transformation of our balanace sheet by eliminating $127 million of senior and convertible debt and future milestones. Next, we received a $25 million payment from our partner Daewoong and successfully completed a $92 million equity offering. The end result is on March 3, 2021 Pro forma cash position was $140 million, which is expected to fund for at least the next 12 months. As David mentioned, we posted strong net revenues for the first quarter of 2021 of $12.2 million, up 16% over the first quarter of 2020 despite the headwinds from the ITC bonds. We recorded most of our Q1 2021 revenue in the second half of the quarter as we continue to sell, under a bond until mid-February. Moving down the P&L, our first quarter of 2021 adjusted gross margin percentage was 60% excluding the $25.5 million settlement payment. We continue to expect our gross margin percentage for fiscal year 2021 to be in the range of 50% to 55%, including the royalties ow under the ITC settlement agreement. Consistent with commentary provided on prior calls, our gross margin will depend on sales levels promotional activity and other factors. Our first quarter 2021 non-GAAP operating expenses were $24.8 million reduced 26% from $33.4 million in the first quarter of 2020. Expenses were lower in 2021 due to operating with a leaner organization during COVID 19 and reduced spending on programs delayed in the first quarter prior to settling the ITC litigation. We do expect our non-GAAP operating expenses may vary quarterly depending on promotional activity and other factors. The first quarter of 2021 was profitable on a net income basis due to the $25.5 million settlement payment received from our partner. Please note, this is a one-time payment impacting only the first quarter of 2021. As a result of the settlement agreement and equity offering, as of May 7, 2021, were $54.1 million shares of common stock outstanding to help with your models, our basic weighted average shares outstanding for the first quarter of 2021 were $37.1 million and our fully diluted weighted average shares outstanding for the first quarter of 2021 were $41.1 million. With that, I'll turn the call back over to David.

Thank you, Lauren. Last week, we brought together our selling team for our first live meeting since COVID-19 shutdowns and the energy across the sales force was palpable. The field is seeing firsthand the value of our esthetic only focus investment in one on one marketing with their practices and our digital focus on millennial, returning media ambassador. our total purchasing accounts, we now have more than 500 I volume neurotoxin accounts earning our co-branded media investment and in less than a year having enrolled 160,000 patients into our consumer loyalty program. In partnership with our customers, know that committed to building a brand millennials dashboard by name. In closing, I would like to take a moment to thank our customers those our rapid bounce back. Our commitment to them has never being stronger. We invested our commitment to them, has never been stronger. We invest in their growth, improve their profit margins and we do this with the brand built from the ground up to appeal to the millennial segment. Lastly, I would like to extend my thanks to all level of employees, who know that customer centricity powers this company and we would not be off to such a strong restart without their unwavering commitment. With that, I'll turn the call over for Q&A. Operator.

[Operator Instructions] Your first question comes from the line of Marc Goodman from SVB Leerink. Your line is now open.

Hi David, can you give us a flavor for what's going on in the broader market? Previously you had talked about 1.5 billion, as I was thinking about the market for this year, is that still a number you're thinking about as it trending higher or lower or the competitors kind of getting back out there doing the same thing as you are just trying to understand like just what's happening behind the scenes? Thanks.

Sure. Thanks for the question Marc. As as we enter now here the second quarter, it's been very impressive to see this market rebound back as quickly as it has, as you heard the fourth quarter was likely the strongest quarter the neurotoxin market ever had and we saw that continue into the first quarter of 2021 whereas you look at the market leader, as an example, their revenue continue to hit all time high, we're in the first quarter you would typically see a dip in revenue relative to the seasonal high period of the core, you didn't see that this year and I think that speaks to the strength of this market. As you pointed out, we estimate 2022 market value will be $1.5 billion and we estimate that the 2021 neurotoxin market will be roughly $1.3 billion. We'll continue to watch those trends as we see the year progresses, but we feel very good that this -- about the market having not only rebounded but that the overall market values will achieve all time high this year, which is certainly playing a role in the overall category growth this year.

And then Lauren, should we expect SG&A to trend up as the year progresses?

Thanks. Thanks for the question. I think if you look at the fourth quarter of last year Mark and I think we talked about this on the year-end call. It's a range that we're really comfortable with, and that was in the middle '20s and a little bit higher on a non-GAAP OpEx basis to be clear.

Your next question comes from the line of Annabel Samimy from Stifel. Your line is now open.

Hi, all. Thanks for taking my question and congratulations on a strong quarter. Getting a little bit granular here, can you tell us whether the $12.2 million was some sort of restocking, given that I think maybe people are running off their inventories with the uncertainty, so how much of was restocking versus just on demand ordering? And secondly, I guess you know now that you're somewhat more free and clear to make some investments with the capital that you have, order, some of the programs you intend to sort of lean into this year and how should we think about, I guess competitors what they're doing and maybe from more of the Sintex investment going on. I know that not just prevents that others are starting to look for some other platforms in the use of social media. So maybe you can talk to us about that a little bit. And then finally it's great that Daewoong was able to give you that $25 million settlement payment. I was wondering if there is any other further assistance they're providing on quarterly basis with regards to the royalty that you might have to pay to --or you do have to pay that, happy merry talks, thanks. Thanks. Do I have to repeat my questions?

Yes we -- we dropped off the call Annabel. We had a disconnect on this side. Do you mind repeating, your question, I'm sorry.

Okay. Sure. All three of them. Great. So I guess the first one was of the $12.2 million, how much of that was restocking by the practices given in the 28.10 probably drew down some of their inventories towards the end of the year under the ITC cloud versus on demand ordering. The second was, if you could provide us with any idea, some investment programs that you're going to have going into the year, now that you have available capital and are kind of free and clear of any other legal overhangs. And then finally, I know that Daewoong had paid a good portion of the settlement fees, given their indemnification Is there any further assistance that we should expect with regard to the royalty payment that you have to make to the Medytox. Thanks.

Sure. Thanks. That about, I'll take the first two. This is David and I'll turn it over to Lauren to address the Daewoong settlement fee portion. Starting out with the revenue in the first quarter, the $12.2 million in revenue was a sharp bounce back for us in terms of our customer base, beginning to place orders once the settlement took place. We continue to watch the reorder patterns and the existing account purchasing rates relative to the fouth quarter and that will give us a confidence in the overall performance of the business going into the second quarter, which is that there is more than just an initial restock that's happening within our custom. What's actually occurring here is that as customers now have clarity around the future of our company, the customers are making larger commitments in terms of the order sizes that they're placing and the number of times that they're ordering with us and so that's why we were confident in our second quarter run rate achieving that $100 million level based on the fact that we're continuing to see the order rates percept beyond the initial March orders well into the second quarter. Separately, as far as the programs are concerned Evolus program is our physician loyalty program. What makes it unique is that, as customers purchase more Jeuveau they receive an investment from Evolus into marketing for their practice. And as we've now entered the second quarter as more accounts by larger quantities, they earn a greater investment from analysts. At the highest level accounts are earning up to $24,000 a year in a marketing investment directly from us, and that's taking place in the form of digital, co-branded media on social media on search. It's also happening out of home where we are…

Annabel, on the settlement, that's right, Daewoong paid us $25.5 million which we booked in the first quarter as -- actually contrast us. Yes, when look at the P&L. They provided us great support, going forward on the royalty basis what we're reporting to you is our gross margin guidance, Team, this is the audio for the file of $50 million to $55 million that's inclusive of paying meditalks and Abbie and letting out what they wound reimburses us. You'll note in the first quarter we ran a very favorable to our annual 50% to 55% guidance business is doing very well, marketing programs are very successful right now.

Thank you. And your next question comes from the line of Louise Chen from Cantor. Your line is now open.

Hi, congratulations on all the progress this quarter and thanks for taking my questions. So, I had a few here. First question I had was, do you have any plans to expand your sales force or marketing efforts given the pickup in sales that you're seeing that are coming for the remainder of the year. Second question is, how do you see sales unfolding beyond the second quarter '21 and then last one is just on product expansion where are you with that, would you expect us to potentially see a new product added to our portfolio by the end of this year. Thank you.

Great, thank you, Louise. I take the first two and I'll hand over the last question thereto Lauren. As far as our plans to expand, I'll start with the sales force, we have made investments throughout the organization since the settlement took place we're we filled various gaps and in the sales force we have expanded by a handful of sales reps as well as our inside sales team. We've also made investments in medical affairs that we believe will continue to drive our long-term growth and as we said on prior calls, we'll continue to make selective investments in pockets where we see the market is underserved or the opportunity supports it. On the marketing side, the Evolux program is our long-term investment proposition, as accounts purchase more you should expect to see our investment in marketing will go up commensurate with our revenue and as these accounts move up to higher tiered so will our investment into those accounts. And we know from the early results we're getting that is we invest more of these accounts will grow faster as a result of it as well. And so we feel that we have the right program that is scalable, as we continue to drive both share penetration, which is really where we've been focused since settlement and will be in the second quarter and then going wider in terms of continuing to add new accounts, as we did last year as you know, last year we added nearly 2,000 new customers to Evolus and in the first part of this year you should expect that growth of new accounts to slow a bit as we focus on our existing customer base and then regain the same momentum we had exiting the year last year as we focus on expanding to new customers in the back half and that really sets the stage for how we think about the back half of the year. The second quarter with $100 million run rate annualized serves as a strong baseline and we believe the foundation by which revenue will continue to build. Now that being said, keep in mind there's seasonality in this market. The neurotoxin market the third quarter is the slowest quarter of the year. And so when you factor for that seasonality, you should expect our business to continue to gain momentum, but of course on a lower procedural volume in the market during the third quarter and in the fourth quarter of course we expect procedural volume will be at an all time high as we exit the year and you'll see sales reflect that as we continue into the back half of the year. And so with that, I'll turn it over to Lauren.

Great. Louise thanks for the question on new product expansion. So if you think about it, we have today Jeuveau approved in the United States and Nuceiva approved in Canada and 31 countries across greater Europe. So our expansion plans there of course are to get the launch early next year in Europe. Additionally, on new fever, we're planning to file in additional countries among them Australia so that's part of the pipeline growth plan is there. Your question also leading to a business development question and the way we're looking at that today is we're very singularly focused on the United and getting ready -- and Canada and getting ready for that European launch next year. When it comes to business development there probably isn't a deal in the space over the last couple of years that we haven't seen the deal flow is a very, very strong. We believe in the quality of our assets, very high quality in terms of data the branding the positioning of it and so as we look at other assets were very particular about it so we are continuing the screen and look but I would expect something from us would probably be next year, not this year. Thank you.

[Operator instruction] Your next question comes from the line of Greg Fraser from Truist Securities. Your line is now open.

Thank you. It's Greg Fraser on for Gregg Gilbert for patients who have gotten Jeuveau can you give us a sense for the mix between those two who are toxin-naive and those who switched from another toxin, and for the folks that have switched from a different toxin what would you say tend to be the key drivers.

Sure. Thanks for the question. We have been tracking our user demographic very closely through our consumer loyalty program, which as I mentioned earlier, we have over 160,000 consumers now in that program and the results are very encouraging. The first is we continue to have a very strong presence of millennial users within our loyalty program. To date, a little over a third of consumers are millennial that are in that Evolus consumer loyalty program and of those millennials half of them are naive to the category, which gives us a lot of confidence in our ability to continue to drive these new patients into the office. Now putting that aside, what's interesting as we get into the second quarter what we're tracking very closely is as our media investment dollars are rising, because of accounts purchasing at higher volumes to gain our advertising dollars. We expect that will continue to drive more new patients into these offices. We're hearing it first hand from the accounts that are benefiting from our advertising dollars and we're tracking those results as well, in terms of consumer interest in the product, and so we'll continue to keep you up to date on those numbers, but early results are very promising.

Thank you. And your next question comes from the lines of Douglas Chow from HCW. Your line is now open.

And your next question comes from the line of Douglas Chow from HCW. Hi, Good afternoon. Thanks for taking the questions. Just obviously -- obviously the bulk of the selling, took place I presume or after this, after the settlement. I mean, so when we look at that $12.2 million. I mean is it fair to think of that you would have sort of sold double what you sold. If you had had sort of a more normal quarter or the settlement that happened say on December 31 and said?

Yes. The large majority of sales in the first quarter occurred after the settlement, which was more specific on February the 19th. So the latter part of the quarter and as we stated earlier, what we, we're surprised with was that that's the momentum continues and has continued well into the second quarter with our customer orders.

Right. And it really allows us to get to -- Doug, this is Lauren. How are you? Allows us to get million run rate on annualized revenue, annualized net revenues Really sets up some nice way for that.

Okay. Yes, I just trying to understand, I mean, and I think, I think Annabel asked about sort of restocking that, that may or may not have taken place. But it sounds like this was really just a resumption of demand and there wasn't sort of people filling sort of trying to build up inventory, it sounds like this was, I mean going out the door from you and indications.

That's exactly right, Doug, as you know, we launched to Jeuveau in May of 2019, and the ramp that we had in the back half of 2019 exiting with just about $19 million in revenue was a very strong ramp, it was one of the top five launches in esthetics as we had messaged that at the time. We believe what you're seeing now, as we enter the second quarter is the resumption of a trend that we left behind obviously, of course due to COVID in the front half of last year and somewhat impacted by the ITC in the back half last year and we're now starting to see the momentum regaining where we left off from the launch.

And just one final question, I mean, when you think about the different customer segments. You've obviously historically focused on the millennials, are you hearing anything about where the, I mean the market sounds to be really strong right now, any particular customer segments that are really driving the market right now?

As you said, the overall market is very strong. There isn't a customer segment that you could look at that, you would say is not rebounding very strongly and we're starting to see, it's not just related to toxins, it's all esthetic procedures, you could argue it's bigger than esthetic, all beauty products are seeing zoom boom is sort of the industry speak that that I hear consistently and we're hearing it from practices. But what's also important here is Doug, as you know, following COVID there was a rebound of new patient of patients, just coming back to get treated, once we got past that initial rebound, this growth has persisted and we're continuing to see it and what's happening is, it's getting fueled by this millennial segment. It is, it will be the largest segment esthetics, we believe over the next two to five years and this consumer demographic is more ready and willing to take action than any of the prior demographics in esthetics as we've measured them and so we do believe that this tailwind is driven by this demographic entering this market at a faster rate than we've ever seen.

And we are now down to our last question for today Vamil Divan from Mizuho Securities. Your line is now open.

Great, thanks for taking the question. So maybe a couple of just to build a little bit on what you've already discussed but one, could you give us just a sense of what you think your share is of the market? We've obviously heard from the other public companies, but just kind of overall maybe for the month of March or exiting March and then previously you sort of comments before COVID before the ITC issued about, being number two market share, is that still something you think maybe within the next year or something you can achieve, maybe you can just kind of update us on your thinking there. And then just on the commercial situation if you just sort of compare where things are now in terms of in-person versus virtual interactions with providers relative to where you were maybe say pre-pandemic like a year ago or so and where things are now and kind of how that trends you see that evolving over the next few months or quarters here. Thanks.

Great, thank you. Vamil. Let me just I'll start share, it's pointed out earlier, because of the bond period, our revenue was significantly impacted in the front half of the year, which is front half of the quarter which is why a large majority of the revenue came into the back half and our share was equally impacted during the first quarter as a result of that. So I don't have a great barometer for share at this point to give you, of course, we can provide some more colors we have in the past around the share range we believe we're trading at but based on our assumption that the second quarter will be operating at a $100 million run rate we expect that our share will trade back into the mid-to-high single digits as we had exited prior to the ITC, and we'll continue to build from there. That being said, as we think about the long term, last year was clearly a setback between COVID and the ITC and we're very pleased now in less than 90 days of having settled the case that our business has come back on as strongly as it has. We're going to continue to invest into these trends, which we believe are very durable trends and they are built on a long-term partnership with these practices given the growth that we're driving in partnership with them and we'll give you an update in terms of how we see those long-term trends playing out as we get into the future quarters. And I'm sorry. There was a third question in there, Lauren.

Yes, I think that Diwan will help us here, I think the last question was how much our practices back up operating versus being virtual. Is that right?

Yes, I guess you had the practices are your interactions with the practice, how much virtual, how much is in person and do you expect a lot more in person going forward or do you think you already sort of some sort of a steady state for the next few months or quarter or two at least.

Yes, we're think business back to normal course we're following all the proper COVID protocols within our sales force but we do have open access into these accounts. It would be on exception that is an office is not comfortable with the sales rep in there and supporting them. Some of the programs that we have do require that one-on-one time with these practices and since they're open they prefer to do that in person over the phone that being said, as you know we have a digital platform that powers this company and since COVID, we've seen the majority of the transactions for Jeuveau coming directly through our Evolus app, and that is what's enabled us to continue to drive our revenue and to do that on a lower expense base than what we had pre-COVID. Matter of fact, we've redirected some of the incremental expense we put back into the Company directly into marketing expenses around the customer to drive their growth. And so on one hand, the practices are open and they're open to seeing our reps, on the other hand, we have a very efficient model that doesn't require us to physically be in the office on a regular basis to take orders. So when we do make the sales call, we spend more time focusing on how we grow their practice, then we do on physically taking orders because our digital platform is the one that's doing that.

Thank you and no further questions at this time. That concludes today's conference call. You may now disconnect.